tiprankstipranks
Trending News
More News >
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
Germany Market
Advertisement

Vertex Pharmaceuticals (VX1) Stock Forecast & Price Target

Compare
23 Followers
See the Price Targets and Ratings of:

VX1 Analyst Ratings

Moderate Buy
25Ratings
Moderate Buy
15 Buy
10 Hold
0 Sell
Based on 25 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VX1 Stock 12 Month Forecast

Average Price Target

€419.14
▲(25.12% Upside)
Based on 25 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is €419.14 with a high forecast of €534.02 and a low forecast of €346.60. The average price target represents a 25.12% change from the last price of €335.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"345":"€345","440":"€440","535":"€535","392.5":"€392.5","487.5":"€487.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":534.02162736,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€534.02</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":419.1385131664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€419.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":346.60057545,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€346.60</span>\n  </div></div>","useHTML":true}}],"tickPositions":[345,392.5,440,487.5,535],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,396.85,407.401663643077,417.95332728615386,428.5049909292308,439.0566545723077,449.60831821538466,460.15998185846155,470.7116455015385,481.2633091446154,491.81497278769234,502.36663643076923,512.9183000738461,523.4699637169231,{"y":534.02162736,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,396.85,398.5645010128,400.2790020256,401.99350303840004,403.7080040512,405.422505064,407.1370060768,408.85150708960003,410.5660081024,412.2805091152,413.995010128,415.70951114080003,417.4240121536,{"y":419.1385131664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,396.85,392.98465965,389.11931930000003,385.25397895000003,381.38863860000004,377.52329825000004,373.65795790000004,369.79261755,365.9272772,362.06193685,358.1965965,354.33125615,350.4659158,{"y":346.60057545,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":469.55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":447.9,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":420.75,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":433.55,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":443.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.65,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":458.35,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":453.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 39, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":384.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":396.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€534.02Average Price Target€419.14Lowest Price Target€346.60
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on DE:VX1
TR | OpenAI - 4o
TR | OpenAI - 4o
€358.49€375.65
Buy
12.13%
Upside
Reiterated
08/28/25
AI Generated ArticleAI Generated Article
Evercore ISI Analyst forecast on DE:VX1
Evercore ISI
Evercore ISI
€441.82€437.4
Buy
30.57%
Upside
Reiterated
08/22/25
Analysts Offer Insights on Healthcare Companies: Brainsway (NASDAQ: BWAY) and Vertex Pharmaceuticals (NASDAQ: VRTX)
BMO Capital Analyst forecast on DE:VX1
BMO Capital
BMO Capital
€454.55
Buy
35.69%
Upside
Reiterated
08/22/25
Vertex Pharmaceuticals: Strong Prescription Growth and Strategic Initiatives Bolster Buy Rating
Bernstein
Hold
Reiterated
08/22/25
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Goldman Sachs Analyst forecast on DE:VX1
Goldman Sachs
Goldman Sachs
€535.17
Buy
59.75%
Upside
Reiterated
08/11/25
Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on DE:VX1
Canaccord Genuity
Canaccord Genuity
€363.64€352.49
Hold
5.22%
Upside
Reiterated
08/06/25
Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord
Guggenheim
€478.56€468.27
Buy
39.78%
Upside
Reiterated
08/06/25
Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Leerink Partners Analyst forecast on DE:VX1
Leerink Partners
Leerink Partners
€431.39€392.8
Hold
17.25%
Upside
Reiterated
08/06/25
Vertex Pharmaceuticals: Hold Rating Amid Mixed Q2 Results and Pain Management Setbacks
Wells Fargo Analyst forecast on DE:VX1
Wells Fargo
Wells Fargo
€394.51
Buy
17.77%
Upside
Upgraded
08/06/25
Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position
Citi
€493.14€471.7
Buy
40.81%
Upside
Reiterated
08/06/25
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Truist Financial Analyst forecast on DE:VX1
Truist Financial
Truist Financial
€445.97€420.24
Buy
25.45%
Upside
Reiterated
08/05/25
Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on DE:VX1
William Blair
William Blair
Buy
Reiterated
08/05/25
Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
H.C. Wainwright Analyst forecast on DE:VX1
H.C. Wainwright
H.C. Wainwright
€471.7€409.95
Buy
22.37%
Upside
Reiterated
08/05/25
Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright
Needham
Hold
Reiterated
08/05/25
Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating
TD Cowen Analyst forecast on DE:VX1
TD Cowen
TD Cowen
€450.26
Buy
34.41%
Upside
Reiterated
08/05/25
Vertex Pharmaceuticals: Strong Buy Rating Amid Robust Financials and Market Potential Despite Setbacks
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on DE:VX1
TR | OpenAI - 4o
TR | OpenAI - 4o
€358.49€375.65
Buy
12.13%
Upside
Reiterated
08/28/25
AI Generated ArticleAI Generated Article
Evercore ISI Analyst forecast on DE:VX1
Evercore ISI
Evercore ISI
€441.82€437.4
Buy
30.57%
Upside
Reiterated
08/22/25
Analysts Offer Insights on Healthcare Companies: Brainsway (NASDAQ: BWAY) and Vertex Pharmaceuticals (NASDAQ: VRTX)
BMO Capital Analyst forecast on DE:VX1
BMO Capital
BMO Capital
€454.55
Buy
35.69%
Upside
Reiterated
08/22/25
Vertex Pharmaceuticals: Strong Prescription Growth and Strategic Initiatives Bolster Buy Rating
Bernstein
Hold
Reiterated
08/22/25
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Goldman Sachs Analyst forecast on DE:VX1
Goldman Sachs
Goldman Sachs
€535.17
Buy
59.75%
Upside
Reiterated
08/11/25
Goldman Sachs Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)
Canaccord Genuity Analyst forecast on DE:VX1
Canaccord Genuity
Canaccord Genuity
€363.64€352.49
Hold
5.22%
Upside
Reiterated
08/06/25
Vertex Pharmaceuticals price target lowered to $411 from $424 at CanaccordVertex Pharmaceuticals price target lowered to $411 from $424 at Canaccord
Guggenheim
€478.56€468.27
Buy
39.78%
Upside
Reiterated
08/06/25
Guggenheim Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Leerink Partners Analyst forecast on DE:VX1
Leerink Partners
Leerink Partners
€431.39€392.8
Hold
17.25%
Upside
Reiterated
08/06/25
Vertex Pharmaceuticals: Hold Rating Amid Mixed Q2 Results and Pain Management Setbacks
Wells Fargo Analyst forecast on DE:VX1
Wells Fargo
Wells Fargo
€394.51
Buy
17.77%
Upside
Upgraded
08/06/25
Vertex Pharmaceuticals: Buy Rating Upgraded to Overweight Amid Promising Pipeline and Strong Financial Position
Citi
€493.14€471.7
Buy
40.81%
Upside
Reiterated
08/06/25
Citi Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Truist Financial Analyst forecast on DE:VX1
Truist Financial
Truist Financial
€445.97€420.24
Buy
25.45%
Upside
Reiterated
08/05/25
Truist Financial Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
William Blair Analyst forecast on DE:VX1
William Blair
William Blair
Buy
Reiterated
08/05/25
Vertex Pharmaceuticals: Strong Financial Performance and Promising Pipeline Justify Buy Rating
H.C. Wainwright Analyst forecast on DE:VX1
H.C. Wainwright
H.C. Wainwright
€471.7€409.95
Buy
22.37%
Upside
Reiterated
08/05/25
Vertex price target lowered to $478 from $550 at H.C. WainwrightVertex price target lowered to $478 from $550 at H.C. Wainwright
Needham
Hold
Reiterated
08/05/25
Vertex Pharmaceuticals: Strong Financials Overshadowed by Challenges in Pain Program Leading to Hold Rating
TD Cowen Analyst forecast on DE:VX1
TD Cowen
TD Cowen
€450.26
Buy
34.41%
Upside
Reiterated
08/05/25
Vertex Pharmaceuticals: Strong Buy Rating Amid Robust Financials and Market Potential Despite Setbacks
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

1 Month
xxx
Success Rate
18/27 ratings generated profit
67%
Average Return
+3.51%
upgraded a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.51% per trade.
3 Months
xxx
Success Rate
19/27 ratings generated profit
70%
Average Return
+6.75%
upgraded a xxx
rating 27 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 70.37% of your transactions generating a profit, with an average return of +6.75% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
19/27 ratings generated profit
70%
Average Return
+14.47%
upgraded a buy rating 27 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 70.37% of your transactions generating a profit, with an average return of +14.47% per trade.
2 Years
xxx
Success Rate
26/31 ratings generated profit
84%
Average Return
+24.75%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 83.87% of your transactions generating a profit, with an average return of +24.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VX1 Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
0
0
0
0
2
Buy
32
33
35
36
34
Hold
25
33
39
40
32
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
57
66
74
76
68
In the current month, VX1 has received 36 Buy Ratings, 32 Hold Ratings, and 0 Sell Ratings. VX1 average Analyst price target in the past 3 months is 419.14.
Each month's total comprises the sum of three months' worth of ratings.

VX1 Financial Forecast

VX1 Earnings Forecast

Next quarter’s earnings estimate for VX1 is €3.95 with a range of €3.70 to €4.28. The previous quarter’s EPS was €3.87. VX1 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.13% of the time in the same period. In the last calendar year VX1 has Outperformed its overall industry.
Next quarter’s earnings estimate for VX1 is €3.95 with a range of €3.70 to €4.28. The previous quarter’s EPS was €3.87. VX1 beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.13% of the time in the same period. In the last calendar year VX1 has Outperformed its overall industry.

VX1 Sales Forecast

Next quarter’s sales forecast for VX1 is €2.61B with a range of €2.52B to €2.69B. The previous quarter’s sales results were €2.55B. VX1 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.26% of the time in the same period. In the last calendar year VX1 has Outperformed its overall industry.
Next quarter’s sales forecast for VX1 is €2.61B with a range of €2.52B to €2.69B. The previous quarter’s sales results were €2.55B. VX1 beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.26% of the time in the same period. In the last calendar year VX1 has Outperformed its overall industry.

VX1 Stock Forecast FAQ

What is DE:VX1’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals’s 12-month average price target is 419.14.
    What is DE:VX1’s upside potential, based on the analysts’ average price target?
    Vertex Pharmaceuticals has 25.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Vertex Pharmaceuticals a Buy, Sell or Hold?
          Vertex Pharmaceuticals has a consensus rating of Moderate Buy, which is based on 15 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Vertex Pharmaceuticals’s share price target?
            The average share price target for Vertex Pharmaceuticals is 419.14. This is based on 25 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €534.02 ,and the lowest forecast is €346.60. The average share price target represents 25.12% Increase from the current price of €335.
              What do analysts say about Vertex Pharmaceuticals?
              Vertex Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Streets Analysts.
                How can I buy shares of Vertex Pharmaceuticals?
                To buy shares of DE:VX1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis